Analyst Davides holds a conference call with CEO Chowdhury to discuss the Company’s non-invasive glucose monitoring device, commercial strategy and regulatory progress with the FDA on March 29 at 10 am hosted by EF Hutton. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMRD:
- Nemaura includes insulin on list of drugs eligible for EU DuoPack license
- Nemaura Includes Insulin on List of Drugs Eligible for EU DuoPack License Agreement
- Nemaura Medical Announces Receipt of Notice from Nasdaq
- Nemaura Medical receives Nasdaq noncompliance notice
- Nemaura Medical price target lowered to $7 from $8 at H.C. Wainwright